Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients

Background As downstream mediators of PI3K /PTEN /AKT /mTORC1 pathway, the AKT isoforms play critical roles in tumorgenesis. Although the pleiotropic effects of AKT1 in breast cancer have been reported, the genetic and epigenetic characteristics of AKT1 promoter region in breast cancer remains to be identified. In this study we aimed to investigate the promoter mutation spectrum, methylation and gene expression pattern of AKT1 and their relationship with breast cancer. Methods By using PCR target sequence enrichment and next-generation sequencing technology, we sequenced AKT1 promoter region in pairs of breast tumor and normal tissues from 95 unselected Chinese breast cancer patients. The methylation of the promoter region and the expression profile of AKT1 in the same cohort were detected with bisulfite next-generation sequencing and qPCR, respectively. Results We identified 28 somatic mutations in 23 of the 95 (24.2%) breast cancer samples. And 19 of the 28 mutations were located in transcription factor (TF) binding sites. In the 23 patients with somatic mutations, no significant change of methylation or expression was found comparing with other patients. AKT1 promoter region was significantly hypo-methylated in tumor compared with matched normal tissue (P = 0.0014) in the 95 patients. The expression of AKT1 was significantly suppressed in tumor tissue (P = 0.0375). In clinicopathological factor analysis, AKT1 showed significant hypo-methylation (P = 0.0249) and suppressed expression (P = 0.0375) in HER2 negative subtype. And a trend of decrease in expression level (P = 0.0624) of AKT1 in the ER negative subtype was observed, which is significantly decreased in basal-like breast tumor (P = 0.0328). Conclusions Hypo-methylation and suppressed expression of AKT1 was observed to be associated with breast cancer in our cohort. The methylation and expression of AKT1 were both significantly associated with HER2 status. The promoter mutation of AKT1 did not show significant association with its methylation and expression status. These results suggested that the promoter mutation, methylation and gene expression of AKT1 may play distinct roles in tumorgenesis of breast cancer and the integrated analysis of methylation and expression of AKT1 might serve as potential biomarkers for diagnosis and classification of breast cancer.

[1]  Jun Wang,et al.  Integrated analysis of gene expression and methylation profiles of 48 candidate genes in breast cancer patients , 2016, Breast Cancer Research and Treatment.

[2]  A. Toker,et al.  Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. , 2009, Cellular signalling.

[3]  William Stafford Noble,et al.  FIMO: scanning for occurrences of a given motif , 2011, Bioinform..

[4]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[5]  Carlos L Arteaga,et al.  Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer , 2011, Breast Cancer Research.

[6]  E. Baracat,et al.  Loss of PTEN expression and AKT activation in HER2-positive breast carcinomas. , 2014, Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia.

[7]  Douglas F. Easton,et al.  Association studies for finding cancer-susceptibility genetic variants , 2004, Nature Reviews Cancer.

[8]  M. Troxell,et al.  PIK3CA-AKT pathway mutations in micropapillary breast carcinoma. , 2013, Human pathology.

[9]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[10]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[11]  A. Toker,et al.  Akt/PKB Signaling in Cancer: A Function in Cell Motility and Invasion , 2006, Cell cycle.

[12]  Stephen L. Abrams,et al.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention , 2014, Oncotarget.

[13]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[14]  A. Dobrovic,et al.  Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies , 2016, Oncotarget.

[15]  K. Offit,et al.  Hereditary cancer predisposition syndromes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Wanqing Chen,et al.  Breast cancer in China. , 2014, The Lancet. Oncology.

[17]  Menghong Sun,et al.  A Functional Polymorphism (rs2494752) in the AKT1 Promoter Region and Gastric Adenocarcinoma Risk in an Eastern Chinese Population , 2016, Scientific Reports.

[18]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[19]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[20]  K. Ikeda,et al.  Association between AKT1 Gene Polymorphism rs2498794 and Smoking-Related Traits with reference to Cancer Susceptibility , 2015, BioMed research international.

[21]  A. Marchetti,et al.  AKT1E17K in human solid tumours , 2008, Oncogene.

[22]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[23]  Brian J. Stevenson,et al.  Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. , 2012, Genome research.

[24]  M. Jeffers,et al.  AKT1E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection , 2016, BMC Cancer.

[25]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[26]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  A. Hamid,et al.  Association of aberrant methylation at promoter regions of tumor suppressor genes with placental pathologies. , 2016, Epigenomics.

[28]  Kyung-Min Lee,et al.  Akt isoform-specific inhibition of MDA-MB-231 cell proliferation. , 2011, Cellular signalling.

[29]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[30]  A. Toker,et al.  The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. , 2010, Molecular cell.

[31]  R. O'Regan,et al.  The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers , 2014, Therapeutic advances in medical oncology.

[32]  Joe Gray,et al.  Genomics: The breast cancer landscape , 2012, Nature.

[33]  J. Slingerland,et al.  PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest , 2002, Nature Medicine.

[34]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[35]  Thomas Lengauer,et al.  BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing , 2005, Bioinform..

[36]  E. Tokunaga,et al.  Akt is frequently activated in HER2/neu‐positive breast cancers and associated with poor prognosis among hormone‐treated patients , 2006, International journal of cancer.